Navigation Links
New therapy for HIV/AIDS eliminates needles and excessive toxicity

o figure out what's happening early on in V(D)J recombination." Understanding how Hermes and other jumping genes work also holds clues to fighting bacterial infections, improving gene therapies and tackling disease-carrying insects, Craig notes. Bacterial jumping genes can protect bacteria from certain antibiotics. Scientists also are studying jumping genes as vectors to carry gene therapies and as potential modifiers to disrupt the growth-controlling genes of organisms such as mosquitoes and medflies.
'"/>

Source:


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
9. Gene therapy for Parkinsons disease moves forward in animals
10. Pulsating ultrasound enhances gene therapy for tumors
11. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV
Post Your Comments:
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Scientists discover gene module underlying atherosclerosis development 2Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 1Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 2Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 3Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI 1002 in Chronic Kidney Disease at the RNA Interference Su 48292 4Industry Recognized and Trusted Leader Bruce Matter Joins Healthcare IT Company Peminic Inc as Company Growth in the Areas of Patient Safety Ris 48289 1Industry Recognized and Trusted Leader Bruce Matter Joins Healthcare IT Company Peminic Inc as Company Growth in the Areas of Patient Safety Ris 48289 2BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights 48286 1BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights 48286 2BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights 48286 3
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3